Idorsia
 | The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. (June 2022) |
| Company type | Public company |
|---|---|
| ISIN | CH0363463438 |
| Industry | |
| Founded | 2017 |
| Founder | Jean-Paul Clozel, Martine Clozel |
| Headquarters | Allschwil, Switzerland |
Key people | Jean-Paul Clozel (CEO), Martine Clozel (Chief Scientific Officer), Guy Braunstein (Chief Medical Officer) |
| Products | clazosentan, daridorexant |
| Revenue | - 828 million CHF (2023) |
Number of employees | > 1200 (2022) |
| Website | http://www.idorsia.ch; http://www.idorsia.com |
Idorsia is a Swiss pharmaceutical research company in Allschwil, near Basel, Switzerland.
History
[edit]After Actelion was bought by Johnson & Johnson in 2017,[1] Idorsia was spun out into a new company and started operating on the same campus where Actelion was founded under the leadership of Actelion founders Jean-Paul Clozel as CEO and Martine Clozel as CSO. The company expects to be profitable in 2025.[2]
In July 2023 due to a disappointing sales ramp-up of the recently approved sleep drug daridorexant, coupled with disappointing trial results in both clazosentan and lucerestat, Idorsia announced layoffs of up to five hundred staff of its one thousand two hundred total employees, to reduce cash burn at its Swiss headquarters by fifty percent.[3][4] The main shareholder Jean-Paul Clozel provided Idorsia with a private loan of CHF 75 Mio.[5]
In the same month, Idorsia sold its operating businesses in Japan and South Korea to the Japanese firm Sosei Heptares for CHF 400 million. This includes the rights to market clazosentan (Piviaz) and daridorexant (Quviviq) in the Asia Pacific region excluding China, plus rights on two other treatments and up to five clinical-stage programs in Idorsia's pipeline.[6]
Products
[edit]Table current as of May 2, 2022, listing the drugs that have reached at least phase 3 trials.[7]
| drug | disease, condition, remarks | phase |
|---|---|---|
| Daridorexant | Insomnia First insomnia drug to improve both night-time symptoms and day-time function[8] |
Approved in the United States and the EU[2] |
| Clazosentan | cerebral vasospasm | Approved in Japan |
| Lucerastat | Fabry disease | Phase 3 failed; research into other applications continuing |
| Selatogrel | Acute mycardial infarction | Phase 3 |
External links
[edit]- Business data for Idorsia AG:
References
[edit]- ^ "Johnson & Johnson Announces Completion of Acquisition of Actelion | Johnson & Johnson". Content Lab U.S. Retrieved 2023-08-21.
- ^ a b "Idorsia-Medikament Quviviq erhält Zulassung in der EU" [Idorsia drug Quviviq gains approval in the EU] (in German). cash.ch. 2022-05-03. Retrieved 2022-05-03.
- ^ Ltd, Idorsia Pharmaceuticals (2023-07-21). "Idorsia announces a cost reduction initiative to be implemented by the end of 2023". GlobeNewswire News Room. Retrieved 2023-08-21.
- ^ Waldron, James (21 Jul 2023). "Sleepless nights for 500 Idorsia Staff".
- ^ Serrar, Karim (2023-08-08). "Bio Revolution: Neu-Bewertung von Biotech-Aktien durch Biokonvergenz". Schweizer Aktien. Retrieved 2023-08-31.
- ^ Smith, Jonathan (2023-07-20). "Idorsia sells APAC businesses to Sosei Heptares for $466 million". OUtsourcing Pharma. Retrieved 2023-09-27.
- ^ "Idorsia Company Profile" (PDF). Idorsia. Retrieved 2022-05-02.
- ^ "The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia". 2022-02-22. Retrieved 2022-05-02.